ClinicalTrials.gg
RecruitingNCT06129474DROPITUpdated May 14, 2026

Deprescribing Inappropriate Proton Pump Inhibitors

An interventional study of Proton Pump Inhibitor deprescribing tool in Inappropriate Prescribing, Reflux Disease and Proton Pump Inhibitors, sponsored by University of Bern. Recruiting at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by University of Bern · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Gastroesophageal Reflux with a site in Switzerland — 13 open to participants now, 14 under way, none of them phase 3. Gastroesophageal Reflux · Switzerland.

Planned enrollment
3rd of 20
400 · median 67
Started
2024
with 1 other
No phase
9 of 31
5 open now
Primary completion
2027-04
later than 7 of 13 live
Registered
26th of 31
by date

Among the 31 studies in Gastroesophageal Reflux with a site in Switzerland, this one is the 3rd largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 26th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

13 of the 31 studies in Gastroesophageal Reflux with a site in Switzerland are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Gastroesophageal Reflux with a site in Switzerland, or all of them as a file.
02

Study summary

The DROPIT Trial is an interventional, open-labelled, cluster-randomized controlled trial conducted in the Swiss primary care setting. It aims to evaluate an intervention to guide the deprescribing of inappropriate proton-pump inhibitors (PPIs). Therefore, the trial investigates whether the study intervention leads to the deprescribing of inappropriate PPI prescription while ensuring noninferiority safety, in comparison to usual care. Additionally, the trail aims to investigate the intervention's impact on other clinical aspects, as well as addressing features of the implementation of the intervention and its cost-effectiveness.

Read the detailed description

Background and rational:

Proton pump inhibitors (PPIs) are the most frequent treatment of gastric acid related disorders. The use of PPIs is increasing, as well as concerns about their inappropriate use. Long-term use of PPIs has been associated with adverse events (e.g., nutritional deficiencies, osteoporosis, infections). Therefore, deprescribing (stopping or reducing dose) PPIs when they are not or no longer indicated is expected to benefit the patients. While general practitioners (GPs) and patients may be reluctant to deprescribing, studies suggest that clinicians would be more comfortable with deprescribing after additional training, and that patients' acceptance increases following recommendations from their doctor. This highlights the importance of providing GPs and patients with the necessary tools for safe deprescribing. In Switzerland, there is evidence of PPI use without adequate indication or dose.

In the pilot survey conducted within the current project, which involved 48 GPs, 55% of them reported often encountering patients who were prescribed inappropriate PPIs, and 58% expressed a desire for a PPI deprescribing guideline. Optimizing PPI use in Switzerland is needed and of interest. Therefore, the investigators aim to conduct a clinical trial to evaluate an intervention to guide deprescribing of inappropriate PPIs. Additionally, alongside the trial, there will be an integrated process evaluation of the intervention, and a cost-effectiveness evaluation.

Study design:

This interventional, open-labelled, cluster-randomized controlled trial in Swiss primary care setting, aims to evaluate an intervention to guide deprescribing of inappropriate PPIs. In this trial, adult patients with inappropriate PPI prescription will be recruited by GPs in the German speaking part of Switzerland. Based on 1:1 cluster randomization of GPs, patients will be assigned to either the control group or to the group receiving an intervention to guide deprescribing of inappropriate PPIs. The control group will receive usual care. The investigators will compare the effectiveness and safety of the intervention with usual care, over a 12-month follow-up period. Alongside the trial, an integrated process evaluation of the intervention and a cost-effectiveness evaluation will be conducted.

Objectives:

The main goal of this study is to evaluate an intervention to guide deprescribing of inappropriate PPIs. Therefore, the main trial aims to investigate if the study intervention leads to the deprescribing of inappropriate PPI prescription (i.e., effectiveness of the intervention), while ensuring noninferiority safety, in comparison to usual care. Additionally, the trial aims to investigate its impact on other clinical aspects, like the number of medications used, the health-related quality of life, and additional safety endpoints.

Alongside the main trial, an integrated process evaluation of the intervention aims to evaluate the quality of the implementation, as well as GPs' and patients' acceptance and fidelity to the intervention, patient typology, and the mechanisms supporting or hindering the success of the intervention.

Also, alongside the main trial, a cost-effectiveness evaluation aims to investigate the cost implications of the

Statistical considerations:

Statistical methods for the main trial The prescribed PPI dose will be quantified using the defined daily dose (DDD). To quantify its change the investigators will 1) estimate the average PPI dose over the 12 months of follow-up using the area under the curve divided by the time under observation and, 2) calculate the relative change from baseline as one minus the ratio between the average prescription and the baseline prescription level. The difference in the change in prescribed PPI dose between the two groups will be calculated using a linear model, adjusted for the baseline dose and including a random effect for the cluster. The difference in the change in upper gastrointestinal symptoms between the two groups will be calculated from a repeated-measures linear mixed-effects model, adjusted for the baseline value and including the intervention group, the timepoint, and the interaction between group and timepoint as fixed effects. Effects of the cluster and patient will be added as random effects. Both intention-to-treat (ITT) and per-protocol analyses need to meet non-inferiority to claim success for the co-primary safety endpoint.

Statistical analyses for other endpoints Repeatedly measured continuous secondary endpoints will be analyzed using the same model as for the safety co-primary endpoint. Count endpoints will be analyzed using a generalized linear mixed model and a negative binomial distribution, including the random effect of the cluster and the time of observation as an offset. Binary endpoints assessed at the end of the follow-up period will be analysed using mixed effects logistic regression, adjusted for the time under observation and including the random effect of the cluster.

Statistical methods for the integrated process evaluation of the intervention The process evaluation will be done based on the Medical Research Council's evaluation framework for complex interventions. Adherence to deprescribing decisions will be investigated using temporal dynamics modelling. Mechanisms of impact will be investigated based on the health action process approach, an established health behaviour change theory. The qualitative part will consist of semi-structured in-depth interviews with both patients and GPs.

Statistical methods for the cost-effectiveness evaluation Health economic analysis will be performed from a Swiss statutory health insurance perspective with a primary time horizon. QALYs will be estimated as the area under the survival curve resulting from utility estimates obtained for the different assessment timepoints during the trial. Utilities will be derived from EQ- 5D-5L questionnaire responses based on published valuation algorithms. A regression-based approach to assess intervention effects will be adopted due to the clustered nature of the trial data and possibility of residual baseline imbalances. The investigators will use Generalized Structural Equation Models (GSEMs), which will allow to simultaneously estimate incremental costs and QALYs (i.e., the intervention effects on costs and QALYs in the regression models), while accounting for the clustered nature of the data.

03

Conditions studied

  • Inappropriate Prescribing
  • Reflux Disease
  • Proton Pump Inhibitors

Keywords

  • Deprescribing
  • Proton pump inhibitors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient of a participating GP.
  2. Age: minimum 18 years old.
  3. Daily PPI intake for minimum 8 weeks.
  4. PPI in one of the following doses:

    • minimum 40mg/day pantoprazole;
    • minimum 40mg/day omeprazole;
    • more than 30mg/day lansoprazole;
    • more than 30mg/day dexlansoprazole;
    • more than 20mg/day esomeprazole;
    • more than 20mg/day rabeprazole.
  5. Sufficient knowledge of German language to understand the trial and follow-up according to GP assessment.

Exclusion criteria

Exclusion Criteria:

  1. Limited according to GP judgement (patients with terminal disease and a life expectancy of less than 12 months.
  2. Unable to provide .
  3. PPI in an appropriate dose (see Appendix Table A1) and with an established indication for long-term PPI, such as:

    • History of bleeding ulcer.
    • Peptic ulcer due to cause other than NSAID or H. Pylori.
    • Barrett's oesophagus.
    • Severe erosive reflux disease (Los Angeles grade C/D).
    • GERD with symptoms or complications (oesophageal ulcer, peptic stricture).
    • Other indications (i.e., Zollinger-Ellison-Syndrome, PPI-sensitive eosinophilic esophagitis, chronic pancreatitis with steatorrhea to enzyme replacement therapy, idiopathic pulmonary fibrosis.)
  4. Two or more of the following medications, or one of the following medications and one or more of the mentioned risk factors mentioned below.

Medications (any dose):

  • Daily use of non-steroidal anti-inflammatory drug (NSAID) for more than 7 days.
  • Antiplatelet therapy.
  • Additional antiplatelet therapy (e.g., ticagrelor or similar).
  • Anticoagulant(s).
  • Systemic (s) for more than 1 month.

Risk factors:

  • History of gastrointestinal ulcer.
  • Age of 75 years and older.
  • Selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) use.
  • Severe concomitant disease with increased risk of GI bleeding according to the GP's assessment (e.g., severe liver disease, neoplasia, nicotine or alcohol abuse).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    DROPIT Intervention

    The study intervention is a patient-centred PPI deprescribing intervention aiming to guide GPs and patients through the process of safely deprescribing inappropriate PPIs.

    Other: Proton Pump Inhibitor deprescribing tool

  • No intervention
    Usual Care

    The reference or control arm will receive usual care. This means that the GPs and patients in this group will conduct their clinical practice as per usual, without receiving the intervention from the study team.

Interventions

  • OtherProton Pump Inhibitor deprescribing tool

    The intervention is targeted to the Swiss Primary care practice. It involves educational material and resources to guide the safe deprescribing of inappropriate PPIs, for both general practitioners and patients.

06

What researchers measure

Primary outcomes

  1. Effectiveness co-primary endpoint: prescribed PPI dose over 12 months follow-up (superiority endpoint).

    Time frame: 12 months

  2. Safety co-primary endpoint: upper gastrointestinal symptoms (Non-inferiority endpoint)

    Co-primary endpoints measured by the Reflux Disease Questionnaire (RDQ), considering the worst of the subscales dyspepsia and gastroesophageal reflux disease (GERD) (i.e.,regurgitation and heartburn subscales combined).

    Time frame: 12 months

Secondary outcomes

  1. Occurrence of reduction of at least 50% of the prescribed PPI dose over the follow-up time.

    Time frame: 12 months

  2. Occurrence of PPI discontinuation

    Stop in PPI prescription as indicated by the general practitioner (GP)

    Time frame: 12 months

  3. Occurrence of PPI sustained discontinuation

    3 months without prescribed PPI

    Time frame: 12 months

  4. Occurrence of a switch to prescription for on-demand use

    Time frame: 12 months

  5. Occurrence of use of alternative anti-reflux treatments

    i.e., alginate-based compounds, anti-acids, H2-blockers

    Time frame: 12 months

  6. Regurgitation

    Measured with the Reflux Disease Questionnaire (RDQ). The RDQ score ranges from 0 (not present) to 5 (severe) per symptom.

    Time frame: 12 months

  7. Heartburn

    Measured with the Reflux Disease Questionnaire (RDQ). The RDQ score ranges from 0 (not present) to 5 (severe) per symptom.

    Time frame: 12 months

  8. Dyspepsia

    Measured with the Reflux Disease Questionnaire (RDQ). The RDQ score ranges from 0 (not present) to 5 (severe) per symptom.

    Time frame: 12 months

  9. Atypical gastrointestinal symptoms

    Symptoms measured by the Reflux Symptom Index (RSI). The RSI scales for each individual item ranges from 0 (no problem) to 5 (severe problem), with a maximum total score of 45.

    Time frame: 12 months

  10. Occurrence of ulcers and/or gastrointestinal bleeding

    Time frame: 12 months

  11. Occurrence of potential side effects of PPI overuse during the conduct of the trial.

    Potential side effects include vitamin B12, iron (Fe), magnesium (Mg), and sodium (Na) deficiencies, osteoporosis, small intestinal bacterial overgrowth (SIBO), anemia, fractures, nephritis, and intestinal infections (C.diff., enteritis-salmonella, campylobacter).

    Time frame: 12 months

  12. Quality of life (EQ-5D-5L)

    Assessed by the European Quality of Life 5-Dimensions 5-Levels (EQ-5D-5L) questionnaire. The VAS score from this questionnaire will be analyzed in the main DROPIT paper, all other questions and the resulting score will be analyzed in the health economic paper conducted alongside the trial.

    Time frame: 12 months

  13. Number of all medications prescribed during the conduct of the trial

    Measured using the Anatomical Therapeutic Chemical (ATC) code

    Time frame: 12 months

Other outcomes

  1. Serious adverse events (SAE)

    A Serious Adverse Event (SAE) (ClinO, Art. 63) is any untoward medical occurrence that results in death or is life-threatening, requires in-patient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or causes a congenital anomaly or birth defect. Upon a SAE, the GP makes the severity assessment of the event following the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: 12 months

  2. Mortality

    Time frame: 12 months

  3. Patients' satisfaction with the trial participation

    Measured by the Study Participant Feedback Questionnaire (SPFQ), handed to at the beginning (baseline), middle (6-month) and end of trial (12-month).

    Time frame: 12 months

  4. Use of alternative anti-reflux treatments (medication)

    After PPI discontinuation and after PPI sustained discontinuation

    Time frame: 12 months

  5. New PPI prescription

    Addressed after PPI discontinuation and after PPI sustained discontinuation

    Time frame: 12 months

07

Study locations

1 of 2 sites recruiting
  • Prof. Dr. med. Dr. phil. Sven Streit
    Bern, 3012, Switzerland
    Not yet recruiting
    • Sven Streit, Prof. Dr. med. Dr. phil. · Contactsven.streit@unibe.ch · +41 31 684 58 75
    • Sven Streit, Prof. Dr. med. Dr. phil. · Principal investigator
  • University of Bern
    Bern, 3012, Switzerland
    Recruiting
    • Sven Streit Prof. Dr. Dr. med · Contactdropit.biham@unibe.ch · +41 31 631 58 70
    • Sven Streit Prof. Dr. Dr. med · Principal investigator
08

References and documents

Publications

  • Schulthess-Lisibach AE, Luthold RV, Tombez C, Weir KR, Zangger M, Chan S, Jenal F, Roumet M, Mattmann Y, Bieri C, Aubert CE, Rodondi N, Zambrano Ramos SC, Trelle S, Neuner-Jehle S, Juillerat P, Barbier M, Inauen J, Streit S, Jungo KT, Vallejo-Yague E. DepRescribing inapprOpriate Proton Pump InhibiTors (DROPIT): study protocol of a cluster-randomised controlled trial in Swiss primary care. BMJ Open. 2025 Jan 20;15(1):e094495. doi: 10.1136/bmjopen-2024-094495. PubMed 39832992 ↗

Individual participant data

Plan to share: Yes — Following informed consent for data sharing, data could be shared upon request to the sponsor-investigator. The data is owned by the sponsor-investigators. In case of data sharing, a data sharing agreement between the external party and the sponsor-investigator will need to be agreed on and signed.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Apr 2027, 30 months after the start.

Of 194 non-industry interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 68. This study's planned 30 months is close to that.

Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Nov 13, 2023
StartActual
Oct 1, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
Dec 31, 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06129474
Lead sponsor
University of Bern
Collaborators
Swiss National Science Foundation, University of Zurich, University of Basel, Insel Gruppe AG, University Hospital Bern, Patientenstelle Zürich, Patientenstelle Basel, Centre Hospitalier Universitaire Vaudois
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Oct 1, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 14, 2026

Study contacts

Sven Streit, Prof. Dr med. Dr. phil.
Contact
sven.streit@unibe.ch
+41 31 684 58 75
Sven Streit, Prof. Dr. med. Dr. phil
principal investigator · University of Bern, Institute of Primary Health Care (BIHAM)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion